Novavax stock soars on license deal with European company Jul 1, 2009
Novavax stock soars on license deal - Washington Business Journal ... Novavax stock soars on license deal ... Novavax has been in the second phase of human clinical testing for the technology on roughly 300 patients. (Washington Business Journal, DC)
The following is an investment opinion release issued by Pennystockchaser.com Jun 22, 2009
Novavax Inc. NVAX, sector: Medical, industry: Biotechnology. Uranium Hunter Corp. URNH, sector: Mining, industry: Exploration. (PR Newswire)
Tips from the journals of the American Society for Microbiology Jun 20, 2009
The researchers from the National Center for Immunization and Respiratory Diseases, Collaborating Centers for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; and Novavax, Inc., Rockville, Maryland report their findings in the June 2009 issue of the Journal of Virology. More than 220,000 hospitalizations and approximately 36,000 deaths are attributed to influenza A viruses each year. (EurekAlert!)
OffTheWallStocks featuring on its newsletter: WIND, OMEX, FR, AGEN, HEB, NVAX Jun 5, 2009
Today's focused alerts include: Wind River Systems (Nasdaq: ), Odyssey Marine Exploration (Nasdaq: ), First Industrial Realty Trust (NYSE: ), Antigenics Inc Del (Nasdaq: ), Hemispherx Biopharma Inc (AMEX: ), Novavax Inc (Nasdaq: ). OffTheWallStocks. (PR Newswire)
GEN reports on efforts to quickly develop swine flu vaccine Jun 3, 2009
Novavax plans to create a virus-like particle-based (VLP) vaccine against the H1N1 strain, which obviates the need for a live virus seed for manufacturing. The VLPs contain the proteins that make the virus' outer shell and the surface proteins, without the RNA required for replication. (EurekAlert!)
Researchers Look for Ways to Deliver a One-Two Punch to Flu Viruses Jun 3, 2009
Biotech firm Novavax, Inc., in Rockville, Md. has begun developing a prototype swine flu vaccine using information the CDC posted to the Global Initiative on Sharing Avian Influenza Data (GISAID) database, launched in 2006 by a number of government organizations, science institutes and universities worldwide (including the World Health Organization, CDC, and the Max Planck Institute for Informatics) to encourage data-sharing in response to the global spread of the. (Scientific American)
1-Star Stocks Poised to Plunge: Novavax? May 9, 2009
1-Star Stocks Poised to Plunge: Novavax ... 1-Star Stocks Poised to Plunge: Novavax ... Based on the aggregated intelligence of 130,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, vaccine maker Novavax (Nasdaq: NVAX) has received the dreaded one-star ranking. (MSNBC -- Business)
Novavax reports wider losses May 9, 2009
Novavax says it spent $7 ... Novavax began development of a vaccine for the N1H1 influenza virus and says it is in contact with government and health authorities about its progress ... Novavax s technology for producing vaccines can cut the manufacturing time in half. (Washington Business Journal, DC)
More of this story May 4, 2009
The Truth wrote on May 3, 2009 11:33 AM:" I hope to shed some light on this subject, so maybe people can understand what is Really Going on with the so called "Swine Flu". This Is nothing more than a psych op, Yes The H1N1 Flu Virus is real, But its not Pandemic strength. First off N1H1 did not come from Swine, It was Gene Spliced at NOVAVAX in Maryland, Publicly traded as NVAX. There Share was at a all time low on March 5th t 0.56 cents a share, on April 28th It Spiked at $3.18 a Share. Now Do... (Westerly Sun, RI)
Ever-changing virus challenges drugmakers May 3, 2009
Companies such as Rockville-based Novavax are trying to cut production times even further. Novavax also grows flu vaccines in cells, but instead of using the actual virus, the company uses genetic information from the virus to create a decoy ... Rahul Singhvi, Novavax's chief executive, said his company can make flu vaccines in up to three months and is working on a swine flu vaccine. (MSNBC -- Health)
Region's biotechs step up efforts to fight swine flu May 2, 2009
Novavax, a Rockville biotech that received an 80 percent boost in its stock price Monday as swine flu first swept across headlines, said it could produce a vaccine in as little as 10 to 12 weeks using an emerging vaccine production technology that uses virus-like particles, rather than the entire virus strain ... We can produce vaccines faster and make them available for first responders before bigger capacity comes online, said Rahul Singhvi, CEO of Novavax, during an analyst call. (Baltimore Business Journal, MD)
Biotechs work to combat swine flu May 1, 2009
Novavax, a Rockville biotech that received an 80 percent boost in its stock price Monday as swine flu first swept across headlines, said it could produce a vaccine in as little as 10 to 12 weeks using an emerging vaccine production technology that uses virus-like particles, rather than the entire virus strain ... We can produce vaccines faster and make them available for first responders before bigger capacity comes online, said Rahul Singhvi, president and CEO of Novavax, during an analyst... (Washington Business Journal, DC)
How Fast Could a Swine Flu Vaccine Be Produced? Apr 30, 2009
At the biotech company Novavax, researchers are testing the use of virus-like particles (VLP), instead of the virus itself, to stimulate a flu immune response ... "We have made vaccines against multiple flu strains and tested them in humans and gotten relevant and robust immune responses, which checks off the major boxes that the technology works against flu," says Rahul Singhvi, president and CEO of Novavax ... Novavax's strategy involves isolating three proteins from the virus that flag the... (Time.com)
Local Company Says It Can Cut Flu Vaccine Production Time In Half Apr 30, 2009
Novavax's seasonal flu vaccine is still in clinical trials ... Novavax is working on something completely different ... In a small lab in Rockville's biotech corridor, Novavax is growing gallons of the virus like particles. (W-USA News, DC)
» Swine flu fears a boon? Apr 29, 2009
-based biotech company Novavax Inc. could see a benefit from the outbreak, as its technology is one of the fastest methods for creating a vaccine. "If the infection escalates and a government body decides to stockpile vaccine, we believe that Novavax is well positioned to capitalize on this opportunity with its recombinant vaccine technology," Piros said in a note to investors ... Novavax shares nearly doubled in price to $2. (Northwest Indiana Times)
Region Prepares for Potential Swine Flu Outbreak Apr 29, 2009
Sources say locally based Novavax is working on a vaccine that could be completed in as soon as 10 weeks. ABC 7 Talkback. (ABC 7 News, DC)
Swine flu fear lifts Novavax stock Apr 28, 2009
Shares of Rockville-based Novavax (NASDAQ: NVAX) rose as much as $2 ... By the closing bell, that frenzy subsided a bit, and Novavax closed up 80 percent to $2 ... Last summer, Novavax announced that its experimental vaccine against one strain of avian influenza produced a strong immune response in humans. (Washington Business Journal, DC)
Flu's bad news but shot in the arm for biotech Apr 28, 2009
Meanwhile, Novavax Inc., of Rockville, Md ... The Bay Area connection: As part of its Pandemic and Bio Defense Fund, Menlo Park's Kleiner Perkins Caufield invested $20 million in Novavax and $30 million in BioCryst. (San Francisco Chronicle -- Business)
Glaxo, Novavax, other drug stocks leap due to swine flu Apr 28, 2009
Novavax, a Maryland-based company that in 2005 turned its attention to flu vaccines, saw its shares leap 80% Monday. Novavax is testing cell-based technologies to enable it to produce a flu vaccine in as little as three months, says equity analyst Elemer Piros at Rodman & Renshaw. (USA Today -- News)
Novavax to get capital infusion Apr 1, 2009
Rockville-based Novavax, which is developing vaccines for influenza and HIV, reported a net loss of $11 million, or 15 cents per share, for the fourth quarter of 2008 compared to a net loss of $9 ... On Tuesday the company also announced a joint venture between Ltd. and Novavax in India, which will be owned 80 percent by Cadila and 20 percent by Novavax, pending approval of the India Foreign Investment Promotion Board ... The partners will develop and commercialize Novavax s seasonal influenza... (Washington Business Journal, DC)
Biotechs go without CFOs in midst of economic recession Mar 13, 2009
At Rockville s Novavax, which is trying to raise $25 million partly to help pay off pending debt, CFO Len Stigliano left in January to be closer to his Pennsylvania home ... We have a very strong financial team, said Novavax s chief executive officer, Rahul Singhvi. (Washington Business Journal, DC)
Novavax taps interim accounting chief Feb 10, 2009
Novavax taps Evdoxia Kopsidas as interim accounting chief - Washington Business Journal ... Novavax taps Evdoxia Kopsidas as interim accounting chief ... A former controller for and , Kopsidas steps in for former Chief Financial Officer Len Stigliano, who had joined Novavax in April 2007 as an interim CFO himself. (Washington Business Journal, DC)
New vaccine against deadliest strain of avian flu tested by University of Pittsburgh scientists Jan 30, 2008
PITTSBURGH, Jan. 29 A vaccine against the most common and deadliest strain of avian flu, H5N1, has been engineered and tested by researchers at the University of Pittsburghs Center for Vaccine Research and Novavax Inc. According to a study published by the Public Library of Science in the Jan. 30 issue of PLoS ONE, the vaccine produced a strong immune response in mice and protected them from death following infection with the H5N1 virus ... The study was funded by Novavax located in... (EurekAlert!)
Sinovac vaccine passes midstage study Dec 25, 2007
Last week, Rockville, M.D.-based Novavax Inc. said its experimental pandemic flu vaccine induced promising immune responses in patients during an early-to-midstage study ... 62 morning trading while shares of Novavax fell 3 cents to $3. (BusinessWeek)
Novavax's new bird flu vaccine could bolster the arsenal against a ... Dec 22, 2007
Novavax's new bird flu vaccine could bolster the arsenal against a pandemic ... Novavax's new bird flu vaccine could bolster the arsenal against a pandemic ... Novavax's new bird flu vaccine could bolster the arsenal against a pandemic. (News-Medical.net)
Novavax Bird Flu Vaccine Shows Promise Dec 21, 2007
Biopharmaceutical company Novavax Inc. said Thursday its experimental pandemic flu vaccine generated promising immune responses in patients during an early-to-midstage study ... The company said an independent data and safety monitoring board reviewed the data and recommended Novavax move to the next stage, which involves testing doses up to 90-micrograms ... Novavax President and Chief Executive Dr. Rahul Singhvi said the company can potentially provide a vaccine that can adjusted to fight a... (Houston Chronicle)
Novavax to halt sales of estrogen product Oct 27, 2007
The facility is expected to be closed in a "few months," according to Novavax. "The goal to exit manufacturing of Estrasorb had been a high priority of the company's board and management team since this activity was not strategic to the company's core vaccine business," said Novavax in a release ... Novavax Inc. (NASDAQ: NVAX) said its core business is developing a vaccine to protect people against pandemic influenza. (Washington Business Journal, DC)
Glaxo, Novartis, Hurt by Drug Setbacks, May Lose Flu-Shot Race Aug 23, 2007
Now the U.S. is preparing another round of funding for companies including Protein Sciences and publicly traded Novavax Inc., based in Malvern, Pennsylvania, to develop flu shots using recombinant DNA.. We were told they could produce a vaccine in less than 12 weeks after the start of a pandemic,'' Robin Robinson, director of pandemic influenza countermeasures for the Health and Human Services Department, said in a telephone interview. (Bloomberg)
BioMed Realty Trust Reports Second Quarter 2007 Financial Results Aug 7, 2007
Portfolio Update During the quarter, the company acquired the following two properties: -- 6114-6154 Nancy Ridge Drive -- three office/laboratory buildings in the Sorrento Mesa submarket of San Diego, California comprising 112,000 square feet that is fully leased to Arena Pharmaceuticals, Inc. -- 9920 Belward Campus Drive -- a 51,181 square foot office/laboratory building in Rockville, Maryland that is fully leased to Novavax, Inc. The company also entered into a joint venture with Prudential... (PR Newswire)
Novavax elects vaccine expert as chairman Jul 28, 2007
In January, Novavax moved its headquarters from Malvern, Pa ... Novavax (NASDAQ: NVAX), though a much smaller company than Chiron, is in a similar space: The Maryland company is developing vaccines to protect against the flu and other viral diseases ... "Having John Lambert on [our] board gives our company another unique competitive advantage," says Novavax President and CEO Rahul Singhvi in a statement. (Washington Business Journal, DC)
Who Still Uses Message Boards?The debacle over posts by Whole Foods CEO John Mackey shows that message boards, relics from the 1980s, continue to thrive. And who's on them may surprise you Jul 20, 2007
TRMP (Trump Entertainment), MCZ (Mad Catz video game accesories), NVAX (vaccine maker Novavax), NPLA (InPlay Technologies) were the most popular over the last four weeks. Mackey, in his alarming lack of judgement, reminded us not only of the dangers of anonymous information exchange, but also of the persistence of pre-Web 1. (Time.com)
People on the Move Jul 11, 2007
Novavax Inc. announced the selection of Len Stigliano as vice president, chief financial officer and treasurer of the Rockville-based producer of vaccines for treatment of infectious diseases. Visicu Inc. appointed Connie D'Argenio as vice president of sales for the Baltimore-based health care information technology and clinical solutions company. (Sunspot.net -- Business)
Business Digest Jul 10, 2007
M. William SalganikBiotechnologyNovamax licensing Wyeth's technologyVaccine maker Novavax Inc. said yesterday that it was licensing Wyeth's virus-like particle technology for use in some human vaccines. Novavax's deal with Wyeth provides for an upfront payment, annual license fees, milestone payments and royalties on any product sales ... Payments to Wyeth could aggregate $5 million through the end of 2008, Novavax said. (Sunspot.net -- Business)
Novavax Vaccine Performs Well in Trial Jun 2, 2007
NEW YORK Novavax Inc. said Friday data from a preclinical trial showed very low doses of its avian flu vaccine still prevented the virus from infecting tested ferrets. Novavax said its virus-like particle H5N1 vaccine protected ferrets from challenges with the H5N1 strain of influenza known commonly as bird flu ... "We are extremely encouraged that even very low doses of our vaccine are proving to be effective in pre-clinical models without the need for adjuvants," said Rick Bright, Novavax's... (Houston Chronicle)
United Industrial plans stock buyback May 12, 2007
Novavax reports earnings decline Novavax Inc. reported a first quarter earnings decline this morning as it spent more on research and development to support the development of its influenza vaccines ... Novavax was based in Columbia until it moved to Malvern, Pa. (Sunspot.net -- Business)
Stocks to Watch May 11, 2007
Novavax Inc. () is expected to report a first-quarter loss of 10 cents a share. Warner Chilcott Ltd. () is expected to post earnings of 18 cents a share for the first quarter. (Fox News)
Novavax flu vaccine works in animals May 4, 2007
"We are on target to file our first vaccine investigational new drug application by midyear," says Novavax chief executive Rahul Singhvi in a statement ... Novavax (NASDAQ: NVAX) plans to start human clinical trials with the vaccine later this year. (Washington Business Journal, DC)
Flu shots may prevent heart attack deaths Apr 19, 2007
Among flu-shot makers are Novartis AG, Sanofi-Aventis SA, GlaxoSmithKline Plc, and MedImmune Inc. As many as 10 drugmakers are developing vaccines specifically against a mutated avian influenza virus, including Novavax Inc.. Researchers used autopsy reports rather than death certificates, improving the accuracy of the findings, they said in the study. (Boston Globe)
Alba Therapeutics taps Church as CFO Apr 17, 2007
He most recently served as vice president, CFO, treasurer, and corporate secretary at Novavax, Inc. Before that, he was CFO, treasurer and corporate secretary at , helping take that company public in December 2000. He will start his new position with Alba on April 23. (Baltimore Business Journal, MD)
Novavax first to use new UMBI lab in Rockville Apr 9, 2007
Members: Not Registered. for free extra services. (Baltimore Business Journal, MD)
Novavax finance chief resigns Apr 8, 2007
Rockville-based Novavax hired Jeffrey Church as finance chief just six months ago ... Church will leave Novavax later this month to accept a position with another company, Novavax says in a statement ... Novavax has named Len Stigliano as interim CFO until a replacement is found. (Washington Business Journal, DC)
Novavax Appoints Interim CFO Apr 6, 2007
April 5 /PRNewswire-FirstCall/ -- Novavax Inc. today appointed Len Stigliano as interim Chief Financial Officer to replace Jeffrey W. Church, who is leaving later this month to accept a position with another company. "We are very disappointed to lose Jeff, but we respect his personal decision," said Novavax President and Chief Executive Officer Dr. Rahul Singhvi ... About Novavax Novavax Inc. (Nasdaq: ) is committed to leading the global fight against infectious disease by creating novel, highly... (PR Newswire)
Novavax stock soars after vaccine report Apr 3, 2007
Novavax says the tests with ferrets more similarly mimic likely human responses than do tests with other lab animals. "This is the first time Novavax has measured the efficacy of our VLP vaccine against a live virus challenge in the very important ferret model," says Novavax's vice president of global influenza programs, Rick Bright, in a statement. (Washington Business Journal, DC)
On The Move For Monday, April 2 Apr 3, 2007
Meanwhile, another drug maker, Novavax (nasdaq: - - ), is also on the rise. The company says one of its new vaccines for a strain of the avian flu shows promising results. (Forbes)
Novavax full-year loss doubles Mar 14, 2007
For all of 2006, Novavax lost $23 ... "2006 was a transitional period for Novavax," said CEO Rahul Singhvi ... Late last year, Novavax closed operations in Malvern, Pa. (Baltimore Business Journal, MD)
Ahead of the Bell: Bird Flu Jan 11, 2007
One-on-one training, charts & more. Realize your trading potential in the world's largest market. (BusinessWeek)
